

World Journal of *Clinical Cases*

World J Clin Cases 2023 November 6; 11(31): 7508-7740



Contents

Thrice Monthly Volume 11 Number 31 November 6, 2023

REVIEW

- 7508 Gut microbiome: New perspectives for type 2 diabetes prevention and treatment
Li SX, Guo Y

MINIREVIEWS

- 7521 Endoscopic management of benign biliary strictures: Looking for the best stent to place
Colombo M, Forcignanò E, Da Rio L, Spadaccini M, Andreozzi M, Giacchetto CM, Carrara S, Maselli R, Galtieri PA, Pellegatta G, Capogreco A, Massimi D, Khalaf K, Hassan C, Anderloni A, Repici A, Fugazza A
- 7530 Antibiotic resistance in patients with liver cirrhosis: Prevalence and current approach to tackle
Liakina V

ORIGINAL ARTICLE

Retrospective Study

- 7543 Analysis of risk factors for postoperative deep vein thrombosis after craniotomy and nomogram model construction
Su ZJ, Wang HR, Liu LQ, Li N, Hong XY
- 7553 Value of ultrasound and magnetic resonance imaging combined with tumor markers in the diagnosis of ovarian tumors
Yang Q, Zhang H, Ma PQ, Peng B, Yin GT, Zhang NN, Wang HB
- 7562 Measurement of combined flap thickness for reconstruction of decubitus ulcer using computed tomography
Kim EC, Park JD, Wee SY, Kim SY
- 7570 Does the advantage of transcutaneous oximetry measurements in diabetic foot ulcer apply equally to free flap reconstruction?
Lee DW, Hwang YS, Byeon JY, Kim JH, Choi HJ

Clinical Trials Study

- 7583 Effects of ulinastatin therapy in deep vein thrombosis prevention after brain tumor surgery: A single-center randomized controlled trial
Tao YN, Han Q, Jiao W, Yang LK, Wang F, Xue S, Shen M, Wang YH

Observational Study

- 7593 Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer
Yang Q, Li LY

- 7610** Efficacy of β_2 -adrenergic receptor agonist combined with corticosteroid in the treatment of children with cough variant asthma

Cao JY, Wang YC, Deng XX

Randomized Controlled Trial

- 7619** Protective effect of sevoflurane on lung function of elderly chronic obstructive pulmonary disease patients undergoing total hip arthroplasty

Yao Y, Zhang MS, Li YB, Zhang MZ

CASE REPORT

- 7629** Sunitinib-induced hyperammonemic encephalopathy in metastatic gastrointestinal stromal tumors: A case report

Hayakawa T, Funakoshi S, Hamamoto Y, Hirata K, Kanai T

- 7635** Simultaneous lateral and subxiphoid access methods for safe and accurate resection of a superior vena cava aneurysm: A case report

Kim SP, Son J

- 7640** Ultrafast power Doppler imaging for ischemic encephalopathy: A case report

Huang LJ, Jiao JF, He Q, Luo JW, Guo Y

- 7647** Intermittent spontaneous ovulation in patients with premature ovarian failure: Three case reports and review of literature

Zhang WY, Wang HB, Deng CY

- 7656** Sneddon's syndrome concurrent with cerebral venous sinus thrombosis: A case report

Heng Y, Tang YF, Zhang XW, Duan JF, Shi J, Luo Q

- 7663** Carcinosarcoma of the deep lobe of the parotid gland in the parapharyngeal region: A case report

Tang YY, Zhu GQ, Zheng ZJ, Yao LH, Wan ZX, Liang XH, Tang YL

- 7673** Malignant peripheral nerve sheath tumor with hemophilic syndrome and bone marrow fibrosis: A rare case report

Li H, Wang L, Wu YH, Chen G, Li HX, Fan LF, Gu M, Jiang CH

- 7680** Comparison of drug concentrations in blood and gastric lavage fluid before and after gastric lavage: A case report

Zhou Y, Tong JL, Peng AH, Xu SY

- 7684** Recurred forehead osteoma disseminated after previous osteoma excision: A case report

Lee DY, Lim S, Yoon JS, Eo S

- 7690** Renal pelvis sarcomatoid carcinoma with renal vein tumor thrombus: A case report and literature review

Guan HY, Wang J, Wang JX, Chen QH, Lu J, He L

- 7699** Ultrasonographic identification of lateral femoral cutaneous nerve anatomical variation in persistent meralgia paresthetica: A case report

Park HW, Ji KS, Kim JH, Kim LN, Ha KW

- 7706** Biliary hemorrhage caused by a malignant small round cell tumor in the common bile duct: A case report
Jin YL, Ruan YJ, Lu GR
- 7712** Successive development of ischemic malignant strokes in a patient with multiple fusiform aneurysms: A case report
Shin DS, Yeo DK, Choi EJ
- 7718** Isolated axillary tumor deposit consistent with primary breast carcinoma: A case report
Li T, Zhang WH, Liu J, Mao YL, Liu S
- 7724** Multiple inflammatory pseudotumor formation after craniopharyngioma resection *via* an extended nasal endoscopic approach: A case report
Wu H, Ding YW, Yan ZC, Wei M, Wang XD, Zhang HZ
- 7732** Huge Bartholin's cyst managed by primary marsupialization: A case report
Li HY, Ding DC

LETTER TO THE EDITOR

- 7738** Do not forget diet and exercise during Ramadan
Ilias I, Tselebis A

ABOUT COVER

Editorial Board Member of *World Journal of Clinical Cases*, How-Ran Guo, DSc, MD, MSc, Full Professor, Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University, Tainan 70428, Taiwan. hrguo@mail.ncku.edu.tw

AIMS AND SCOPE

The primary aim of *World Journal of Clinical Cases* (WJCC, *World J Clin Cases*) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Si Zhao; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Salim Surani, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/2307-8960/editorialboard.htm>

PUBLICATION DATE

November 6, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Observational Study

Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer

Qing Yang, Li-Yuan Li

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0
Grade B (Very good): 0
Grade C (Good): C, C
Grade D (Fair): 0
Grade E (Poor): 0

P-Reviewer: Reynolds EC, Australia; Yerke LM, United States

Received: August 23, 2023

Peer-review started: August 23, 2023

First decision: September 13, 2023

Revised: October 9, 2023

Accepted: October 23, 2023

Article in press: October 23, 2023

Published online: November 6, 2023



Qing Yang, Li-Yuan Li, The Second Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230031, Anhui Province, China

Corresponding author: Qing Yang, MMed, Doctor, The Second Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, No. 117 Meishan Road, Hefei 230031, Anhui Province, China. cbdcnmyy929@sina.com

Abstract

BACKGROUND

Although Liu-Wei-Bu-Qi capsule (LBC) inhibits tumor progression by improving the physical condition and immunity of patients with lung cancer (LC), its exact mechanism of action is unknown.

AIM

To through compound multi-dimensional network of chemical ingredient-target-disease-target- protein-protein interaction (PPI) network, the principle of action of Chinese medicine prescription was explained from molecular level.

METHODS

Network pharmacology and molecular docking simulations were used to analyze the relationship among the main components, targets, and signaling pathways of LBC in treatment of LC.

RESULTS

From the analysis, 360 LBC active ingredient-related targets and 908 LC-related targets were identified. PPI network analysis of the LBC and LC overlapping targets identified 16 hub genes. Kyoto Encyclopedia of Genes and Genomes analysis suggested that LBC can target the vascular endothelial growth factor signaling pathway, Toll-like receptor signaling pathway, prolactin signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway and HIF-1 signaling pathway in the treatment of LC. Molecular docking simulations showed that quercetin had the best affinity for MAPK3, suggesting that quercetin in LBC may play an important role in the treatment of LC.

CONCLUSION

The results showed that the active ingredients in LBC can play a crucial role in the treatment of LC by regulating multiple signaling pathways. These results provide insights into further studies on the mechanism of action of LBC in the treatment of

LC.

Key Words: Liu-Wei-Bu-Qi capsule; Lung cancer; Network pharmacology; Molecular docking; Active ingredients; Signaling pathways

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The network pharmacological and molecular docking study of Liu-Wei-Bu-Qi capsule (LBC) on lung cancer revealed that LBC's active ingredients target multiple signaling pathways, including the endothelial growth factor, toll-like receptor, prolactin, FoxO, PI3K-Akt, and HIF-1 pathways. Quercetin, found in LBC, showed promising affinity for MAPK3, highlighting its potential role in lung cancer treatment. These findings provide valuable insights into the mechanisms of action of LBC and pave the way for further investigations into its therapeutic effects on lung cancer.

Citation: Yang Q, Li LY. Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer. *World J Clin Cases* 2023; 11(31): 7593-7609

URL: <https://www.wjgnet.com/2307-8960/full/v11/i31/7593.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v11.i31.7593>

INTRODUCTION

Lung cancer (LC) was the leading cause of cancer-related deaths and had the second highest incidence rate worldwide in 2020[1]. Since most of the patients are usually diagnosed when they are in the middle or advanced stage of disease, surgery is usually not an option, which necessitates the use of chemotherapy or radiotherapy. However, conventional chemotherapy and radiotherapy are associated with significant side effects and suppression of the immune system, leading to premature termination of treatment[2].

Traditional Chinese medicine (TCM) has high efficacy, is associated with mild and few side effects and is being explored as a safe and effective adjuvant therapy for LC. Liu-Wei-Bu-Qi capsule (LBC) is a type of TCM that consists of Panax ginseng C. A. Mey (Shengshaishen, SSS), Hedysarum Multijugum Maxim (Huangqi, HQ), Alpiniae Oxyphyllae Fructus (Yizhiren, YZR), Polygonati Odorati Rhizoma (Yuzhu, YZ), Cinnamomi Cortex (Rougui, RG) and Citrus reticulata (Chenpi, CP). LBC can reduce radiotherapy and chemotherapy-induced side effects such as anorexia and hair loss, and improve the immune response of tumor patients[3]. Herbal compounds have been shown to have anti-tumor effects, including Ginsenoside Rh2, a ginseng extract that converts M2 macrophage phenotype to M1 phenotype in the microenvironment and prevents migration of LC cells[4]. Astragalus polysaccharide, the main active component of HQ, inhibits the proliferation of human LC cells A549 and NCI-H358 by inhibiting NF-κB signaling pathway[5].

Although many herbal compounds have been found to have anti-tumor effects, most studies have focused on the anticancer effects of individual components rather than herbal complexes. The mixing of herbal compounds to achieve maximum efficacy can be aided by computer technologies such as network pharmacology and molecular docking simulation, which can be used to accurately screen the active ingredients and targets of Chinese herbs and predict their mechanisms in treatment of different diseases. Network pharmacology is the use of 'multi-dimensional-target-pathway' network diagrams to identify genes and proteins interactions and thus predict potential mechanism of drug action in the treatment of various diseases[6]. In this study, we used network pharmacology and molecular docking simulation to predict the potential mechanism of LBC action in the treatment of LC. Findings from this study will provide insights into further studies involving *in vitro* and *in vivo* models. The workflow diagram is shown in Figure 1.

MATERIALS AND METHODS

Identification of the active ingredients in LBC

A search of TCMSD and TCMID databases was done to identify the active ingredients of LBC. The information on potential targets of the active ingredients was imported into UniProt for searching and normalization, and the structure data files were downloaded in Pubchem after removing duplicates. The structures of the active ingredients were imported into Discovery Studio 2017R2 to predict the ADMET parameters of the LBC. Compounds with ADMET_Absorption_Level of 0, 1, 2 and ADMET_Solubility_Level of 1, 2, 3, 4 were included for further analysis. The links to the databases and platforms used in this study are shown in Table 1.

Screening of LC-related targets and identification of overlapping targets

Lung cancer-related targets were identified using the search term "lung cancer" to search the GeneCards[7], DisGeNet[8], TTD[9] and OMIM databases[10]. Overlapping targets from the four databases were selected as LC-related targets and were used for further studies. Active ingredients-related and therapeutic LC-related targets were imported into Venn

Table 1 The addresses of databases

Database	Address
TCMSP	http://www.tcmspw.com/tcmsp.php
TCMID	http://www.megabionet.org/tcmid/
UniProt	https://www.uniprot.org/
PubChem	https://pubchem.ncbi.nlm.nih.gov
SwissTargetPrediction	http://www.swisstargetprediction.ch/
Genecards	https://www.genecards.org
TTD	http://bidd.nus.edu.sg/group/ttd/ttd.asp
OMIM	https://omim.org/
DisGeNET	https://www.disgenet.org/home/
Venn platform	https://bioinfogp.cnb.csic.es/tools/venny/index.html
String	https://string-db.org/
DAVID 6.8	http://david.ncifcrf.gov
Omicstudio	https://www.omicstudio.cn/tool
PDB	https://www.rcsb.org

2.1.0 platform and a Venn diagram was plotted to identify overlapping targets.

Construction of protein-protein interaction networks and identification of hub genes

Protein-protein interaction (PPI) networks were constructed by uploading the overlapping targets to STRING database and setting the parameters as 'human' and 'confidence ≥ 0.400 '. The PPI network information was imported into Cytoscape 3.8.2 software based on the topological algorithm of cytoHubba plugin to identify hub genes and perform cluster analysis to find gene clusters and derive sub network[11].

Gene ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analysis

We used the gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis pipeline ($P < 0.05$) in the DAVID 6.8 database[12] to predict the main biological processes and signaling pathways associated with LBC-based treatment of LC based on the hub genes identified. The results were visualized using Cytoscape software.

Construction of 'ingredient-target-pathway' diagram

Compound information, all key targets and potential signaling pathways were imported into the Cytoscape 3.8.2 to create the 'ingredient-target-pathway' network and analyze the multicomponent-target-pathway mechanism of LBC-based treatment of LC.

Molecular docking simulation of crucial targets and ingredients

We collected the small molecule compounds of the main active ingredients of Chinese medicine in mol2 format, downloaded the crystal structures of structurally complete, high-resolution, ligand-bearing targets from the PDB protein database, and imported the data into Discovery Studio 2017 R2 to perform molecular docking. The binding energies and hydrogen bond numbers were calculated[13].

RESULTS

Identification of potential targets for LBC

We identified 66 active ingredients in LBC, with the main structures being phenylpropanoids, flavonoids, alkaloids and terpenoids. We then used Discovery Studio 2017R2 software to find and screen 57 active ingredients of LBC, including 14 of SSS, 12 of ZHQ, 12 of YZR, 4 of YZ, 11 of RG, and 4 of CP (Table 2). We further obtained 55 active ingredient in the target database ($P > 0.9$), and 360 potential targets were identified after removing duplicate values.

Identification of LC-related targets and construction of Venn diagram

Disease-related targets were selected from the GeneCards DisGeNET, TTD, and OMIM databases using the search term 'lung cancer', with 908 targets being identified after deleting duplicate values. Venn diagram analysis showed that there was an overlap of 69 targets between active ingredient-related targets and LC-related targets (Figure 2A). A 'Herbs-Ingredients-Targets' interaction network was then constructed to illustrate the relationship among herbs, compounds and




Figure 1 Workflow diagram for assessing the treatment of lung cancer using Liu-Wei-Bu-Qi capsule. LBC: Liu-Wei-Bu-Qi capsule; LC: Lung cancer; TCMPSP: Traditional Chinese Medicine Systems Pharmacology; ADME: Absorption, Distribution, Metabolism, Excretion; DS: Discovery Studio; TTD: Therapeutic Target Database; OMIM: Online mendelian inheritance in man; DAVID: Database for Annotation, Visualization and Integrated Discovery; STRING: Search tool for the retrieval of interacting genes; PPI: Protein-protein interaction.




Figure 2 Interaction network diagram of Liu-Wei-Bu-Qi capsule-based treatment of lung cancer. A: The Venn diagram of targets that overlapped between lung cancer-related and active ingredient-related targets; B: The 'Herbs-Ingredients-Targets' interaction network. Purple hexagons indicate Chinese herbs, blue squares indicate ingredients; yellow ovals indicate targets. LC: Lung cancer; LBC: Liu-Wei-Bu-Qi capsule; RG: Rou-Gui; SSS: Sheng-Shai-Shen; ZHQ: Zhi-Huang-Qi; YZR: Yi-Zhi-Ren; YZ: Yu-Zhu; CP: Chen-Pi.

targets (Figure 2B).


Construction of the PPI network and screening of hub targets

The PPI network showed a total of 69 nodes (target proteins) and 719 edges (protein interactions). The darker the red color of the target indicates the more targets that can effectively interact with the target among the predicted LC-related targets (Figure 3A). Based on the five parameters (MNC, DEGREE, MCC, CLONESS, EPC), top 20 targets were obtained and the 16 targets that overlapped from the five parameters were considered to be hub targets (Figure 3B). The PPI network of 16 hub targets was plotted using Cytoscape, with a darker blue color indicating a larger degree value (Figure 3C, Table 3).


GO enrichment analysis

GO enrichment analysis was carried out by importing 69 targets into DAVID 6.8 database. The analysis identified 259 biological processes (BP), 78 molecular functions (MF) and 38 cellular components (CC) that were associated with the targets. The top 20 BP, CC, and MF terms were selected for visualization according to the number of genes, with significance set at $P < 0.5$ (Figure 4). The main BP terms associated with LBC-based treatment of LC were cellular


A



B



C



DOI: 10.12998/wjcc.v11.i31.7593 Copyright ©The Author(s) 2023.

Figure 3 Protein-Protein Interaction Network. A: All target protein interaction networks; B: Venn diagram based on five parameters; C: The network of hub targets.




Figure 4 Gene Ontology enrichment results. A: Key terms of biological processes analysis results; B: Key terms of molecular functions analysis results; C: Key terms of cellular components analysis results. DNA: Deoxyribonucleic acid; RNA: Ribonucleic acid.




Figure 5 Kyoto Encyclopedia of Genes and Genomes pathway enrichment diagram.

response to chemical stimulus, cellular response to oxygen-containing compound, response to organic substance, cellular response to organic substance, and response to chemical. The main MF terms included compound binding of heterocyclic, organic cyclic and identical, transcription factor activity, and direct ligand-regulated sequence-specific DNA binding. The main CC terms were membrane raft, microdomain, and region, nucleoplasm and nuclear part.

KEGG pathway analysis

KEGG enrichment analysis was performed for potential targets through DAVID6.8 database. The top 10 pathways were estrogen signaling pathway, thyroid hormone signaling pathway, VEGF signaling pathway, toll-like receptor signaling pathway, prolactin signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, HIF-1 signaling pathway, sphingolipid signaling pathway, neurotrophin signaling pathway (Figure 5, Table 4). Suggesting that LBC capsule ingredients played a role in the treatment of lung cancer through the above pathways.

Construction of the 'ingredients-target-pathway' network

The information on each individual herb including active compounds, key targets and pathways were imported into Cytoscape-3.8.2 to build the 'herbs-compounds-targets-pathways' network (Figure 6A). Analysis using cytoHubba showed that estrogen and thyroid hormone signaling pathways are closely associated with LBC-based treatment of LC. The network of these two pathways and related targets and active components was constructed (Figure 6B).

Molecular docking simulation

Molecular docking simulations were carried out between the ingredients, protocatechuic acid, Dianthramine, quercetin, kaempferol and quercetin, and the hub targets. The results showed that the binding energy of the targets and their related compounds were all negative. A negative binding energy indicates that the ligand can spontaneously bind to the receptor, with a smaller value indicating a more stable binding energy. Most of the potential targets docked with quercetin, with the docking energy of EGFR, ESR1, HSP90AA1, SRC, HIF1A, TNF and MAPK3 with quercetin being -21.6109, -37.218, -40.1408, -37.7868, -38.3202, -61.2015, -50.4514, respectively. Among them, MAPK3 had the lowest docking binding energy with quercetin (Figure 7, Table 5).

DISCUSSION

LC is the most common malignant tumor worldwide, and its high morbidity and mortality rates pose a serious threat to public health[14]. Chinese herbal medicine has been shown to improve quality of life of patients by inducing apoptosis, inhibiting cell proliferation, and suppressing tumor metastasis. It also extends patients' treatment cycles by reducing the side effects of radiotherapy and activating the body's immunity[15]. Ginseng suppresses tumor migration and invasion and improves the immune function of the body through regulating the interaction between tumor-associated macrophages and LC[4].

In this study, data mining was used to identify the core active ingredients of LBC. Network pharmacology was then used to predict the multiple mechanisms of LBC-based inhibition of LC. Venn diagram analysis found that there was an overlap of 69 targets between targets of LBC active ingredients and LC, indicating that LBC may utilize the 69 genes as

Table 2 Active ingredients and absorption, distribution, metabolism and excretion parameters of Liu-Wei-Bu-Qi capsule

No.	Compound	PubChem CID	ADMET-SOLUBILITY-level	ADMET-absorption-level	Herb
SSS1	Arachidonate	5312542	2	1	SSS
SSS2	Celabenzine	442847	3	0	SSS
SSS3	Deoxyharringtonine	285342	2	0	SSS
SSS4	Dianthramine	441562	3	1	SSS
SSS5	Frutinone A	441965	2	0	SSS
SSS6	Ginsenoside rh2	119307	2	2	SSS
SSS7	Girinimbine	96943	1	0	SSS
SSS8	Gomisin B	6438572	1	1	SSS
SSS9	Kaempferol	5280863	3	0	SSS
SSS10	Maackiain	91510	2	0	SSS
SSS11	Malkangunin	90473155	3	0	SSS
SSS12	Panaxadiol	73498	1	0	SSS
SSS13	Protopine	4970	2	0	SSS
SSS14	Suchilactone	132350840	2	0	SSS
ZHQ1	3,9,10-Trimethoxypterocarpan	15689655	2	0	ZHQ
ZHQ2	7-O-methylisomucronulatol	15689652	2	0	ZHQ
ZHQ3	Antibiotic FA 2097	102059896	3	0	ZHQ
ZHQ4	Betulinic acid	64971	1	2	ZHQ
ZHQ5	Calycosin	5280448	3	0	ZHQ
ZHQ6	Formononetin	5280378	3	0	ZHQ
ZHQ7	Hederagenin	73299	1	1	ZHQ
ZHQ8	Isoflavanone	160767	2	0	ZHQ
ZHQ9	Isorhamnetin	5281654	3	0	ZHQ
ZHQ10	Kaempferol	5280863	3	0	ZHQ
ZHQ11	Kumatakenin	5318869	3	0	ZHQ
ZHQ12	Quercetin	5280343	3	1	ZHQ
YZR1	(+)-delta-cadinene	441005	2	1	YZR
YZR2	Caryophyllene oxide	1742210	2	0	YZR
YZR3	Chrysin	5281607	3	0	YZR
YZR4	Daucosterol	5742590	2	2	YZR
YZR5	Globulol	12304985	2	0	YZR
YZR6	Isocyperol	14076604	2	0	YZR
YZR7	Linolenic acid	5280934	2	1	YZR
YZR8	Nootkatol	182645	2	0	YZR
YZR9	O-cymene	10703	3	0	YZR
YZR10	Oleic acid	445639	2	2	YZR
YZR11	Protocatechuic acid	72	4	0	YZR
YZR12	Valencene	9855795	2	1	YZR
YZ1	4',5,7-trihydroxy-6,8-dimethyl-homoisoflavanone	46886731	2	0	YZ
YZ2	4',5,7-trihydroxy-6-methyl-8-methoxy-homoisoflavanone	46886730	3	0	YZ

YZ3	N-cis-Feruloyltyramine	6440659	3	0	YZ
YZ4	P-Coumaroyltyramine	5372945	3	0	YZ
RG1	(-)-alpha-cedrene	6431015	2	0	RG
RG2	(-)-Caryophyllene oxide	1742210	2	0	RG
RG3	()-Sativene	11275742	2	0	RG
RG4	(+)-Aromadendrene	11095734	2	0	RG
RG5	Beta-Cubebene	93081	2	0	RG
RG6	Copaene	19725	2	0	RG
RG7	Diisobutyl phthalate	6782	2	0	RG
RG8	Junipene	1796220	2	0	RG
RG9	Ledene	10910653	2	0	RG
RG10	Linoleic acid	5280450	2	1	RG
RG11	Oleic acid	445639	2	2	RG
CP1	5,7-Dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one	676152	3	0	CP
CP2	Citromitin	12303287	2	0	CP
CP3	Naringetol	932	3	0	CP
CP4	Nobiletin	72344	2	0	CP

Table 3 Analysis of topological parameters of key targets

Name	Closeness	Betweenness	Degree
TP53	0.839506	0.095155	56
EGFR	0.790698	0.051782	51
ALB	0.781609	0.077526	50
ESR1	0.747253	0.054759	47
HSP90AA1	0.764045	0.074274	47
SRC	0.73913	0.035499	45
HIF1A	0.731183	0.023561	44
MAPK3	0.723404	0.033332	43
TNF	0.708333	0.027768	41
MAPK1	0.660194	0.018393	34
PTGS2	0.660194	0.013252	34
SMAD3	0.635514	0.007272	30
AR	0.618182	0.005023	29
STAT1	0.623853	0.00514	29
MMP9	0.62963	0.006427	29
IGF1R	0.623853	0.00413	28

Table 4 Kyoto Encyclopedia of Genes and Genomes pathway enrichment information

Pathway	Count	P value
Estrogen signaling pathway	11	1.09E-08
Thyroid hormone signaling pathway	10	5.77E-08

VEGF signaling pathway	7	5.6E-07
Toll-like receptor signaling pathway	8	1.92E-06
Prolactin signaling pathway	7	2.44E-06
FoxO signaling pathway	8	1.27E-05
PI3K-Akt signaling pathway	13	3.76E-05
HIF-1 signaling pathway	7	4.45E-05
Sphingolipid signaling pathway	7	5.48E-05
Neurotrophin signaling pathway	7	5.77E-05

VEGF: Vascular endothelial growth factor.



Table 5 Molecular docking for key targets and their related compounds

Targets	PDB ID	Compounds	Binding energy (kcal/mol)
TP53	4MZR	protocatechuic acid	-42.1348
ALB	4BKE	Dianthramine	-49.0138
ESR1	4ZNH	quercetin	-37.218
		kaempferol	-37.1051
HSP90AA1	3WQ9	quercetin	-40.1408
		kaempferol	-38.241
SRC	1Y57	quercetin	-37.7868
HIF1A	1L8C	quercetin	-38.3202
		kaempferol	-49.377
MAPK3	2ZOQ	quercetin	-61.2015
TNF	2E7A	quercetin	-50.4514
MAPK1	1TVO	formononetin	-48.1226

therapeutic targets in the treatment of LC. PPI protein network map analysis identified 16 important key targets, including tumor-related targets such as TP53, EGFR, HSP90AA1, HIF1A, and MAPK3. TP53 is a crucial tumor suppressor gene and an emerging target for tumor gene targeting therapy, which strictly regulates the initiation of the cell cycle and is able to repair damaged DNA[16]. Upregulation of the HSP90AA1 gene is associated with decrease in immunity and inhibition of the ability of DNA to repair itself[17]. EGFR is a member of ErbB β family of tyrosine kinase receptors and is considered a driver gene in tumor development[18]. VEGF is an important target in the inhibition of tumor progression, and its expression levels are negatively correlated with progression and prognosis of LC[19]. These results suggest that LBC contain a large number of antitumor compounds.

GO enrichment analysis showed that LBC components may induce apoptosis by regulating the cellular oxidative stress response through modulation of transcription factors and other factors in the treatment of LC. KEGG enrichment analysis showed that 13 and 11 potential targets were related to the PI3K-AKT and estrogen signaling pathway, respectively. Dysregulation of the PI3K/AKT pathway is associated with tumorigenesis, as well as high-grade and advanced tumors of LC. The PI3K-AKT-mTOR signaling pathway is associated with cell proliferation, differentiation, migration, apoptosis and protein synthesis, and is activated in a variety of tumors to promote tumorigenesis[20]. Hamilton DH found that targeting estrogen receptor signaling with fulvestrant enhanced immunity and reduced chemotherapy-induced cytotoxicity in LC patients. He also found that estrogen signaling pathways affect LC progression through induction of EMT[21]. Effects of estrogen signaling pathway in LC are mainly mediated through nongenetic and genetic pathways [22]. This suggests that LBC may be involved in regulating these pathways to exert anti-tumor effects in LC.


The results of molecular docking simulations demonstrated that the compounds have affinity for the potential targets. These results further demonstrate the reliability network pharmacology in predicting active compounds and their targets in relation to their interaction with LC. The targets with the highest potential to dock with quercetin were EGFR, ESR1, HSP90AA1, SRC, HIF1A, and TNF MAPK3, with binding energies of -21.6109, -37.218, -40.1408, -37.7868, -38.3202, and -61.2015, respectively. Quercetin had the best affinity for MAPK3. This illustrated that quercetin may be a crucial compound in the LBC-based treatment of LC.




DOI: 10.12998/wjcc.v11.i31.7593 **Copyright** ©The Author(s) 2023.

CONCLUSION

In this study, we used network pharmacology to integrate information from various databases and perform preliminary validation using molecular docking to elucidate the characteristics of LBC for the treatment of LC through “multi-components-targets-pathways”. However, since the internal environment of organisms are complex, the active compounds, key targets and mechanism of action of LBC in the treatment of LC need to be verified using *in vivo* experiments. Results from such studies will provide more scientific basis for the use of LBC in the treatment of LC patients.








Figure 7 Molecular docking simulations of targets and compounds. A: Docking of HIF1A and kaempferol; B: Docking of HIF1A and quercetin; C: Docking of MAPK1 and formononetin; D: Docking of SRC and quercetin; E: Docking of TNF and quercetin; F: Docking of MAPK3 and quercetin; G: Docking of

HSP90AA1 and kaempferol; H: Docking of HSP90AA1 and quercetin; I: Docking of ALB and dianthramine; J: Docking of TP53 and protocatechuic acid; K: Docking of ESR1 and kaempferol; L: Docking of ESR1 and quercetin.

ARTICLE HIGHLIGHTS

Research background

Lung cancer (LC) is the second highest disease in the world in terms of incidence rate and the main cause of cancer-related deaths.

Research motivation

Liu-Wei-Bu-Qi capsule (LBC) can reduce radiotherapy and chemotherapy-induced side effects such as anorexia and hair loss, and improve the immune response of tumor patients, and improve the quality of life for patients.

Research objectives

The purpose of this study is to investigate the potential targets and signaling pathways of LBC in the treatment of LC.

Research methods

Network pharmacology and molecular docking simulations were used to analyze the relationship among the main components, targets, and signaling pathways of LBC in treatment of LC.

Research results

The analysis results indicate that the main component for treating LC in LBC may be quercetin, which may be used to treat LC by regulating the endothelial growth factor signaling pathway, Toll like receptor signaling pathway, prolactin signaling pathway, FoxO signaling pathway, PI3K-Akt signaling pathway, and HIF-1 signaling pathway. Molecular docking simulations indicate that quercetin has the best affinity for MAPK3, suggesting that quercetin in LBC may play an important role in the treatment of LC.

Research conclusions

The results showed that the active ingredients in LBC can play a crucial role in the treatment of LC by regulating multiple signaling pathways.

Research perspectives

Predicting potential targets and mechanisms for LBC treatment of LC based on network pharmacology and molecular docking.

FOOTNOTES

Author contributions: Yang Q and Li LY contributed equally to this work; Yang Q and Li LY designed the study; Yang Q contributed to the analysis of the manuscript; Yang Q and Li LY were involved in the data and writing of this article; and all authors have read and approved the final manuscript.

Institutional review board statement: This study adopts network pharmacology and molecular docking simulation methods without requiring hospital ethical approval.

Informed consent statement: This study did not involve human experiments and does not require the signing of an informed consent form.

Conflict-of-interest statement: Yang Q and Li LY Declaration that there is no conflict of interest.

Data sharing statement: No additional data are available.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Qing Yang 0009-0007-8575-3069.

S-Editor: Liu JH

L-Editor: A

P-Editor: Yuan YY

REFERENCES

- Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: [33538338](#) DOI: [10.3322/caac.21660](#)]
- Li ZH**, Yu D, Huang NN, Wu JK, Du XW, Wang XJ. Immunoregulatory mechanism studies of ginseng leaves on lung cancer based on network pharmacology and molecular docking. *Sci Rep* 2021; **11**: 18201 [PMID: [34521875](#) DOI: [10.1038/s41598-021-97115-8](#)]
- Zuo HL**, Zhang QR, Chen C, Yang FQ, Yu H, Hu YJ. Molecular evidence of herbal formula: a network-based analysis of Si-Wu decoction. *Phytochem Anal* 2021; **32**: 198-205 [PMID: [32519355](#) DOI: [10.1002/pca.2965](#)]
- Li H**, Huang N, Zhu W, Wu J, Yang X, Teng W, Tian J, Fang Z, Luo Y, Chen M, Li Y. Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rh2. *BMC Cancer* 2018; **18**: 579 [PMID: [29783929](#) DOI: [10.1186/s12885-018-4299-4](#)]
- Wu CY**, Ke Y, Zeng YF, Zhang YW, Yu HJ. Anticancer activity of Astragalus polysaccharide in human non-small cell lung cancer cells. *Cancer Cell Int* 2017; **17**: 115 [PMID: [29225515](#) DOI: [10.1186/s12935-017-0487-6](#)]
- Li X**, Wei S, Niu S, Ma X, Li H, Jing M, Zhao Y. Network pharmacology prediction and molecular docking-based strategy to explore the potential mechanism of Huanglian Jiedu Decoction against sepsis. *Comput Biol Med* 2022; **144**: 105389 [PMID: [35303581](#) DOI: [10.1016/j.combiomed.2022.105389](#)]
- Safran M**, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirota-Madi A, Olender T, Golan Y, Stelzer G, Harel A, Lancet D. GeneCards Version 3: the human gene integrator. *Database (Oxford)* 2010; **2010**: baq020 [PMID: [20689021](#) DOI: [10.1093/database/baq020](#)]
- Piñero J**, Bravo À, Queralt-Rosinach N, Gutiérrez-Sacristán A, Deu-Pons J, Centeno E, García-García J, Sanz F, Furlong LI. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. *Nucleic Acids Res* 2017; **45**: D833-D839 [PMID: [27924018](#) DOI: [10.1093/nar/gkw943](#)]
- Chen X**, Ji ZL, Chen YZ. TTD: Therapeutic Target Database. *Nucleic Acids Res* 2002; **30**: 412-415 [PMID: [11752352](#) DOI: [10.1093/nar/30.1.412](#)]
- Hamosh A**, Scott AF, Amberger JS, Bocchini CA, McKusick VA. Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. *Nucleic Acids Res* 2005; **33**: D514-D517 [PMID: [15608251](#) DOI: [10.1093/nar/gki033](#)]
- Bader GD**, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. *BMC Bioinformatics* 2003; **4**: 2 [PMID: [12525261](#) DOI: [10.1186/1471-2105-4-2](#)]
- Huang DW**, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, Guo Y, Stephens R, Baseler MW, Lane HC, Lempicki RA. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. *Nucleic Acids Res* 2007; **35**: W169-W175 [PMID: [17576678](#) DOI: [10.1093/nar/gkm415](#)]
- Jin X**, Awale M, Zasso M, Kostro D, Patiny L, Reymond JL. PDB-Explorer: a web-based interactive map of the protein data bank in shape space. *BMC Bioinformatics* 2015; **16**: 339 [PMID: [26493835](#) DOI: [10.1186/s12859-015-0776-9](#)]
- Yang D**, Liu Y, Bai C, Wang X, Powell CA. Epidemiology of lung cancer and lung cancer screening programs in China and the United States. *Cancer Lett* 2020; **468**: 82-87 [PMID: [31600530](#) DOI: [10.1016/j.canlet.2019.10.009](#)]
- Wang Y**, Zhang Q, Chen Y, Liang CL, Liu H, Qiu F, Dai Z. Antitumor effects of immunity-enhancing traditional Chinese medicine. *Biomed Pharmacother* 2020; **121**: 109570 [PMID: [31710893](#) DOI: [10.1016/j.biopha.2019.109570](#)]
- Donehower LA**, Soussi T, Korkut A, Liu Y, Schultz A, Cardenas M, Li X, Babur O, Hsu TK, Lichtarge O, Weinstein JN, Akbani R, Wheeler DA. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas. *Cell Rep* 2019; **28**: 1370-1384.e5 [PMID: [31365877](#) DOI: [10.1016/j.celrep.2019.07.001](#)]
- Zuehlke AD**, Beebe K, Neckers L, Prince T. Regulation and function of the human HSP90AA1 gene. *Gene* 2015; **570**: 8-16 [PMID: [26071189](#) DOI: [10.1016/j.gene.2015.06.018](#)]
- Harrison PT**, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. *Semin Cancer Biol* 2020; **61**: 167-179 [PMID: [31562956](#) DOI: [10.1016/j.semcancer.2019.09.015](#)]
- Ghafoori S**, Burkenroad A, Pantuck M, Almomani B, Stefanoudakis D, Shen J, Drakaki A. VEGF inhibition in urothelial cancer: the past, present and future. *World J Urol* 2021; **39**: 741-749 [PMID: [32361873](#) DOI: [10.1007/s00345-020-03213-z](#)]
- Tan AC**. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). *Thorac Cancer* 2020; **11**: 511-518 [PMID: [31989769](#) DOI: [10.1111/1759-7714.13328](#)]
- Lin Z**, Reierstad S, Huang CC, Bulun SE. Novel estrogen receptor- α binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer. *Cancer Res* 2007; **67**: 5017-5024 [PMID: [17510434](#) DOI: [10.1158/0008-5472.Can-06-3696](#)]
- Hsu LH**, Chu NM, Kao SH. Estrogen, Estrogen Receptor and Lung Cancer. *Int J Mol Sci* 2017; **18** [PMID: [28783064](#) DOI: [10.3390/ijms18081713](#)]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

